Salute e Benessere
ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
Dr. Anna Wu , Founder of ImaginAb, commented, "We are very pleased that Telix recognizes the potential of our novel biological technology platform including enabling Telix to explore new disease areas with state-of-the-art radiotherapeutic technology. These radiopharmaceutical agents represent the culmination of significant effort and resources by our scientific team. I extend my congratulations to everyone at ImaginAb for reaching this significant milestone. This transaction further validates our novel minibody platform."
Dr. Wu continued, "With the sale of our radiopharmaceutical platform, ImaginAb will continue the development of its CD8 platform. We are encouraged that numerous pharmaceutical and biotech companies have incorporated our technology in their immuno-oncology clinical trials."
Jefferies LLC and Stifel, Nicolaus & Company, Incorporated served as financial advisors to ImaginAb on the transaction.
ImaginAb, Inc. is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies that maintain the specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available positron emission tomography (PET) and optical imaging technology, these novel targeting agents are able to bind specifically to cell surface targets.
The company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, Innoviva,
Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb's pipeline and technology, visit www.imaginab.com .
The 89Zr CD8 ImmunoPET technology ( ) is a [89Zr]-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8+ cells in patients. CD8+ cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8+ cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.
The Optical PSMA Imaging Agent ( is a fluorescent labelled minibody that binds the PSMA receptor present on cancer cells including prostate cancer and is used for quantitative, non-invasive PET imaging of PSMA+ cells in patients undergoing surgery to remove cancerous tissue . As such, imaging of PSMA + cells may be used to guide clinicians during surgery to identify cancerous tissue and aid tissue resection.
Logo - https://mma.prnewswire.com/media/2603972/ImaginAb_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/imaginab-inc-innovative-biologics-technology-platform-acquired-by-telix-to-enable-next-generation-therapeutic-assets-discovery-302357703.html